vaccinatierespons er wordt geen aandoening bestudeerd nvt
Conditions
Interventions
Phase 1: There is one intervention and one control group. The intervention
group have to take paracertamol for 24 hours (1000 mg / 8h) starting directly
after the vaccination. The control group take
Sponsors
RIVM
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - good health - able to perform the study according to the procedures - informed consent present
Exclusion criteria
Exclusion criteria: - history of acute or chronic hepatitis B - earlier hepatitis B vaccination - evidence of a serious disease, that needs immunosuppresive treatment - a known primary or secondary immunodeficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase 1: Antibody concentrations prior to and 1 month after the third vaccination (booster vaccination) will be measured. Antibody concentrations expected to be 65% lower in participants that used paracetamol prophylactically. This expectation is based on findings in baby's (Prymula et al., 2009). Phase 2: Antibody concentrations prior to and 1 month after the third vaccination (booster vaccination) will be measured. It is expected that the titers in the groups treated therapeutically with paracetamol will be inbetween the control and prophylactically treated group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Alterations in the functionality of specific lymfocyte subpopulations in blood (1 month after the third vaccination) of participants that used paracetamol prophylactically. | — |
Countries
Netherlands
Outcome results
None listed